News

Results suggest that post-operation intravenous iron therapy could both prevent anemia and offset logistical issues of identifying iron deficiency.

This analysis highlights the increased risk among those with psoriasis for developing such ocular conditions as conjunctivitis, dry eye, and conjunctival hyperemia.

A study found many anaphylaxis patients didn’t receive adrenaline, the first-line treatment. Adrenaline use correlated with better outcomes in adults and children.

Martinez explains the benefit of IBAT inhibitors for improving pruritus in children with Alagille syndrome and PFIC.

Caution may be needed when prescribing 5 mg of oral minoxidil to patients with alopecia and pericardial risk factors such as systemic lupus erythematosus.

The pivotal trial investigating sozinibercept combination therapy failed to meet the primary endpoint of mean change in BCVA at 52 weeks.

The approval is based on data from the phase 3 EAGLE-2 and EAGLE-3 trials.

Goel describes the clinical impact of having 2 newly approved second-line PBC therapies and looks ahead to what’s next and where more research is needed.

Lammert describes the lack of developments in autoimmune hepatitis care over the past several decades and points to what might be next in disease management.

Axsome’s phase 3 trial shows solriamfetol significantly improves ADHD symptoms, with a 45% mean reduction in AISRS scores and onset as early as week 1.

These data highlight the comparability of Humira, the adalimumab originator, to the drug’s biosimilars in terms of efficacy in treating psoriasis.

Positive topline results from PORTOLA show treatment with zetomipzomib resulted in steroid-sparing biochemical remissions in AIH.

New study highlights discrepancies in anaphylaxis severity scoring, emphasizing the need for a unified classification to improve treatment.

Mitchell reviews FDA-approved drugs for reducing alcohol use, which ones can be used in patients with liver disease, and other therapies on the horizon.

FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.

Khandelwal discusses advancements in intraocular lens (IOL) categories and the patient's role in choosing more innovative options.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

Schilsky describes lingering challenges and unmet needs in Wilson disease and highlights recent innovations in monitoring and diagnosis.

Khandelwal shares insight and key takeaways for the optimization of intraocular lens selection in practice.

A new study found that the time it takes to diagnose alpha-gal syndrome has improved from 5.3 years to 28 days since 2011, but disparities remain based on education level.

Veeral Sheth, MD, is joined by the CEO of Neurotech to discuss the historic approval of revakinagene taroretcel (ENCELTO) for macular telangiectasia type 2.

Repka describes the complications of the US healthcare system and how to advance interactions in advocacy efforts.

Goel explains the importance of second-line therapies and describes the role PPARs play in PBC treatment, including 2 newly approved therapies.

Repka dives into the role of advocacy in shaping ophthalmologic policies and ensuring equitable patient care.

Lammert describes the clinical impact of having 2 new second-line PBC therapies, challenges to their uptake, and areas where more research is needed.

These data highlight the long-term maintenance of bimekizumab responses among individuals with psoriasis, looking at bio-naïve and bio-switched patients.

A study found that genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.